|Bid||1.50 x 2200|
|Ask||1.70 x 800|
|Day's Range||1.5000 - 1.5400|
|52 Week Range||1.2800 - 9.1400|
|Beta (3Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.33|
AMES, Iowa & SAN DIEGO-- -- Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease negativity rate of 86% and post-consolidation MRD negativity of 100% Safety data from this study indicate the combination treatment regimen was well tolerated with no regimen limiting toxicities observed NewLink Genetics Corporation announced ...
Charles Link has been the CEO of NewLink Genetics Corporation (NASDAQ:NLNK) since 2003. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...
NewLink Genetics Corporation (NLNK) reported today that Merck has begun the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated). This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by Merck in July 2016 and is anticipated to be completed in 2019.
AMES, Iowa, Nov. 09, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that data from three separate trials are being presented at the Society for Immunotherapy of.
AMES, Iowa, Nov. 06, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the following abstracts have been published and are now available on the Society.
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
AMES, Iowa, Nov. 02, 2018 -- In a release issued under the same headline yesterday by NewLink Genetics Corporation (NASDAQ:NLNK), the balance statement included in the press.
NewLink (NLNK) delivered earnings and revenue surprises of 52.38% and -94.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Ames, Iowa-based company said it had a loss of 20 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss ...
AMES, Iowa, Nov. 01, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the third quarter 2018 and reviewed recent highlights.
NewLink Genetics Corporation (NLNK) announced today that an abstract with data pertaining to the use of the Company's investigational immuno-oncology molecule, indoximod, in combination therapy for patients with newly diagnosed acute myeloid leukemia (AML) has been accepted for an oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to be held at the San Diego Convention Center, San Diego, CA, December 1-4th, 2018. “We are pleased to have an abstract accepted for oral presentation at this year’s ASH Annual Meeting,” said Charles J. Link, Jr, MD, Chairman and Chief Executive Officer.
NewLink Genetics Corporation (NLNK), a clinical stage biopharmaceutical company focused on developing novel immuno-oncology therapeutic candidates, announced today it will present at the Stifel 2018 Healthcare Conference. The conference is being held on November 13 – 14 at the Lotte New York Palace Hotel in New York City, New York. NewLink Genetics is a clinical stage biopharmaceutical company focused on developing novel immuno-oncology product candidates to improve the lives of patients with cancer.
NewLink (NLNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results and to give an update on its clinical development activities. NewLink Genetics' senior management team will host the conference call, which will be open to all listeners. Access to the live conference call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call.
NewLink Genetics Corporation (NASDAQ:NLNK), a US$87.8m small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...
Despite exceeding bottom-line expectations, NewLink Genetics Corp (NASDAQ: NLNK ) plummeted Wednesday on second-quarter sales that were nearly 50 percent below projections. Stifel Nicolaus sees little ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...